RVPH · Reviva Pharmaceuticals Holdings, Inc. · Investor Relations
$0.39
+0.04 (+10.76%)
At close · May 14
Return incl. dividend (before tax)
Going-concern doubt
— flagged Nov 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year after the date the consolidated financial statements are issued.”View the 10-Q filed Nov 13, 2026
Market Cap
$6.33M
Shares
13.11M
Volume · May 14
742.02K
Avg daily vol (48 sessions)
985.8K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
Past events
| Date | Event | Type |
|---|---|---|
| 2026-09-29 | Lytham Partners Fall 2026 Investor Conference | Conference |
| 2026-06-24 | OTC Life Sciences Virtual Investor Forum | Event |
| 2026-06-22 | BIO International Convention | Event |
| 2026-05-28 | Lytham Partners Spring 2026 Investor Conference | Conference |
| 2026-05-20 | A.G.P. Annual Healthcare Company Showcase | Event |
| 2026-04-27 | Reviva Pharmaceuticals (RVPH) Fireside Chat: Developing brilaroxazine a novel dual-modulator for multiple neuropsychiatric indication including schizophrenia, bipolar disorder, and depression | Webcast |
| 2026-01-15 | Lytham Partners 2026 Investor Healthcare Summit | Webcast |
| 2026-01-12 | 44th Annual J.P. Morgan Healthcare Conference | Conference |
| 2026-01-11 | Sachs 9th Annual Neuroscience Innovation Forum | Event |
| 2025-11-03 | Spartan Capital Securities Second Annual Investor Conference | Conference |
| 2025-11-02 | CNS Summit 2025 Poster Presentation | Presentation |
| 2025-10-10 | KOL Webinar Hosted by Alliance Global Partners | Event |
| 2025-10-09 | Roth Healthcare Opportunities Conference | Conference |
Key facts
CIK
1742927
CUSIP
76152G209
13F (30d)
15 filings
4 filers
Visit website
Investor relations